ABSTRACT
Objective: To explore psoriasis vulgaris efficacy of the narrow band UVB therapy combined with compound glycyrrhizin. Methods: The study made it clear diagnosis for patients admitted to our hospital 45 patients with psoriasis vulgaris were randomly divided into experimental group with 25 cases(narrow band UVB therapy combined with compound glycyrrhizin) and control group with 20 cases(only narrow-band UVB irradiation), in order to compare and analyze the treatment effect, the incidence of adverse reactions and symptoms before and after treatment PASI score recorded. Results: The difference was not statistically significant about PASI score of patients in the experimental group and the control group before treatment(t=0.153, P>0.05). But the difference of PASI score was statistically significant between two groups of patients after treatment(t=4.675, P<0.05). The effective rate of treatment in patients of the experimental group was 92%and 75%in the control group. The adverse symptoms in the experimental group and control group were 20% and 60% respectively. The differences were statistically significant (x2=47.908, P<0.05). Conclusion: Narrow band UVB combined with compound glycyrrhizin treatment of psoriasis with respect to only a narrow band ultraviolet therapy have significant therapeutic effect, and it can effectively reduce the incidence of adverse symptoms. It is worth popularizing in clinical.
ABSTRACT
Objective To observe the clinical efficacy of psoriasis treated with avermectin A and astragalus and detect the changes of TNF-a in serum. Preliminarily study the anti-inflammatory and immunomodulatory mechanism of avermectin A and astragalus in the treatment of psoriasis. Methods 20 patients were randomly recruited into a control group (9 cases) and a treatment group (11 cases). Another 20 healthy people were recruited for comparison. The control group was administrated with avermectin A orally, 0.2±0.6 mg/kg·d, with the symptoms turning better, reduced the dosage till the recovery, the treatment group was injected with astragalus injection on the therapeutic basis of the control group. Detect and compare the levels of TNF-α in the serum of the patients with psoriasis before and after the treatment in both groups, then make a contrast to the healthy people. Results 20 patients got clinical cure. The level of TNF-α in the serum of healthy persons is 11.7± 6.7 ng/L, and the level of TNF-α in the serum of psoriasis patients before treatment is (45.4±12.4) ng/L and (46.4±16.9) ng/L in the treatment group and the control group respectively. Compared with healthy control group, the difference is significant. After treatment, is the TNF-αlevels dropped to (13.8± 5.4) ng/L and (20.9±6.3) ng/L in the treatment group and the control group respectively, showing no significant difference compared with healthy control group. The difference between the two group is also significant. Conclusion The efficacy of treating psoriasis with avermectin A and astragalus is better than using avermectin A exclusively. The mechanism may lie in its inhibiting the formation of TNF-α and so thus exerting the anti-inflammatory and immune regulatory functions.